| Date Filed | Type | Description |
| 10/10/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 10/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/10/2023 |
3
| Eureka Therapeutics, Inc. (10% Owner) has filed a Form 3 on Estrella Immunopharma, Inc. |
| 10/05/2023 |
8-K
| Amended existing or entered into new employment agreement with an officer |
| 10/05/2023 |
4
| Owl Creek Asset Management, L.P. (10% Owner) has filed a Form 4 on Estrella Immunopharma, Inc.|
Txns:
| Disposed of 255,000 shares
@ $10.86, valued at
$2.8M
|
|
| 10/05/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 08/18/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/31/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/26/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/19/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/12/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"TradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash New York – July 12, 2023 – TradeUP Acquisition Corp. , a publicly traded special purpose acquisition company, announced that it will hold a special meeting of stockholders of TradeUP on Monday, July 31, 2023 at 9:00 a.m. Eastern Time to vote on, among others, the proposed business combination with Estrella Biopharma, Inc. , a preclinical-stage biopharmaceutical company focusing on cancer therapeutics. On September 30, 2022, the parties entered into a definitive business combination agreement . On July 11, 2023, the registration statement on Form S-4 containing a proxy statement/prospectus relat..." |
|
| 07/12/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/11/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
|